Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07024602 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis
A Phase 1 study of Plaque Psoriasis, sponsored by Ascletis Pharma (China) Co., Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
- 1
- Study location
NCT07024602 is a Phase 1 study of Plaque Psoriasis that is actively recruiting participants, run by Ascletis Pharma (China) Co., Limited. The registered enrollment target is 94 participants, below the 414-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07024602, a Phase 1 study of Plaque Psoriasis, is actively recruiting participants, sponsored by Ascletis Pharma (China) Co., Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, food effect of ASC50 tablets in healthy adult participants and adult participants with mild to moderate plaque psoriasis.
Conditions Studied
Interventions
- DRUG ASC50 tablets or matching placebo
Study Locations (1)
Florida
- Ascletis Clinical Site - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2025-06 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07024602
The ClinicalTrials.gov registry entry for NCT07024602 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 414-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (77% lower). The listed sponsor is Ascletis Pharma (China) Co., Limited, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which ASC50 tablets or matching placebo is the first listed.
NCT07024602 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07024602 about?
NCT07024602 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis". This is a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, food effect of ASC50 tablets in healthy adult participants and adult participants with mild to moderate plaque psoriasis...
What is the current status of trial NCT07024602?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2025-06. Estimated completion is 2026-06.
What conditions does trial NCT07024602 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT07024602?
The interventions under investigation include: ASC50 tablets or matching placebo (DRUG).
Who is sponsoring clinical trial NCT07024602?
This trial is sponsored by Ascletis Pharma (China) Co., Limited, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07024602 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation
COMPLETED · Phase 1
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
RECRUITING · Phase 2
-
Guselkumab Immunogenetics
RECRUITING · Phase 4
-
Bimekizumab in Plaque Psoriasis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.